The European Network for Light Ion Hadron Therapy (ENLIGHT) was established in 2002 to coordinate European efforts on hadron therapy (radiotherapy performed with protons and light ions instead of high-energy photons). The ENLIGHT network is formed by the European Hadron Therapy Community, with more than 300 participants from 20 different countries. A major success of ENLIGHT has been uniting traditionally separate communities so that clinicians, physicists, biologists, and engineers with experience and interest in particle therapy work together. ENLIGHT has been a successful initiative in forming a common European platform and bringing together people from diverse disciplines. ENLIGHT demonstrates the advantages of regular and organized exchanges of data, information, and best practices, as well as determining and following strategies for future needs in research and technological development in the hadron therapy field.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/HP.0b013e3182606520 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing Proton Therapy: A Review of Geant4 Simulation for Enhanced Planning and Optimization in Hadron Therapy.
J Med Signals Sens
November 2024
Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Article Synopsis
- Proton therapy is an advanced cancer treatment that uses precise proton beams to destroy cancer cells while minimizing damage to surrounding healthy tissues.
- The study investigates the effectiveness of the Geant4 Monte Carlo simulation software, which models the interaction between proton beams and the human body for better treatment planning.
- By reviewing published articles from 2002 to 2023, researchers found that Geant4 simulations are both reliable and accurate, making them useful for optimizing and assessing proton therapy systems based on real-world experimental data.
Multidisciplinary treatment of a rare rapidly progressive intracranial myxoid mesenchymal tumor of uncertain differentiation FET-CREB fusion-negative.
Neurol Sci
December 2024
Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Background: Non-meningothelial intracranial mesenchymal tumors are a heterogeneous group of central nervous system neoplasms endowed with great variability clinically and histologically. For this precise reason, significant difficulties exist in specifically cataloguing tumor entities with such distant characteristics and such uncertain clinical course.
Case Description: In an attempt to increase the knowledge inherent in this type of central nervous system lesions we report a case of a rare and unusual myxoid mesenchymal tumor of difficult anatomopathological classification characterized by rapid progression and optimal therapeutic response after combined surgical and radiotherapy treatment, with histo-molecular definition and DNA methylation profile.
Investigating LETd optimization strategies in carbon ion radiotherapy for pancreatic cancer: a dosimetric study using an anthropomorphic phantom.
Med Phys
December 2024
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg, Germany.
Background: Clinical carbon ion beams offer the potential to overcome hypoxia-induced radioresistance in pancreatic tumors, due to their high dose-averaged Linear Energy Transfer (LETd), as previous studies have linked a minimum LETd within the tumor to improved local control. Current clinical practices at the Heidelberg Ion-Beam Therapy Center (HIT), which use two posterior beams, do not fully exploit the LETd advantage of carbon ions, as the high LETd is primarily focused on the beams' distal edges. Different LETd-boosting strategies, such as Spot-scanning Hadron Arc (SHArc), could enhance LETd distribution by concentrating high-LETd values in potential hypoxic tumor cores while sparing organs at risk.
View Article and Find Full Text PDFValidation of Light-Ion Quantum Molecular Dynamics (LIQMD) model for hadron therapy.
Phys Med
December 2024
Department of Biological Sciences, Tokushima University, Tokushima 770-8503, Japan. Electronic address:
Purpose: This study aims to validate the Light-Ion Quantum Molecular Dynamics (LIQMD) model, an advanced version of the QMD model for more accurate simulations in hadron therapy, incorporated into Geant4 (release 11.2).
Methods: Two sets of experiments are employed.
On the microdosimetric characterisation of the radiation quality of a carbon-ion beam and the effect of the target volume thickness.
Phys Med Biol
December 2024
NPL-National Physical Laboratories, Teddington, United Kingdom.
Microdosimetry is gaining increasing interest in particle therapy. Thanks to the advancements in microdosimeter technologies and the increasing number of experimental studies carried out in hadron therapy frameworks, it is proving to be a reliable experimental technique for radiation quality characterisation, quality assurance, and radiobiology studies. However, considering the variety of detectors used for microdosimetry, it is important to ensure the consistency of microdosimetric results measured with different types of microdosimeters.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!